Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis

References

• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310–1315.
   PubMed Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533–539.
   PubMed Web of Science ®Google Scholar
• Kim TD, le Coutre P, Schwarz M, et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012; 97: 883–889.
   PubMed Web of Science ®Google Scholar
• Gora-Tybor J, Medras E, Calbecka M, et al. Real-life comparison of severe vascular events and other non-hematological complications in CML patients treated with second line nilotinib or dasatinib. Blood 2013; 122(21): Abstract #1491.
   Web of Science ®Google Scholar
• Rea D, Mirault T, Raffoux E, et al. Identification of patients (PTS) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib, using risk stratification for cardiovascular diseases (CVD). Blood 2013; 122(21): Abstract #2726.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kim DW, et al. Analysis of the cardiovascular risk profile of Ph + leukemia patients treated with ponatinib. J Clin Oncol 2013; 31(15 Suppl. 1): Abstract #7048.
   Web of Science ®Google Scholar
• Lipton J, Chuah C, Guerci-Bresler A, et al. Epic: A pase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood 2014; 124(21): Abstract #519.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Khoury HJ, et al. Long-term evaluation of vascular toxicity in patients with Ph + leukemias treated with bosutinib. J Clin Oncol 2014; 32(5 Suppl.): 336–337: Abstract #7060.
   Google Scholar
• Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58: 2020–2045.
   PubMed Web of Science ®Google Scholar
• Higgin JPT GS, eds. 2011 Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from: www.cochrane-handbook.org. Accessed December 1, 2014.
   Google Scholar
• Sterne JAC HJ, Reves BC on behalf of the development group for ACROBAT- NRSI. December 1, 2014. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT-NRSI). Version 1.0.0 [September 2014]. The Cochrane Collaboration. Available from: https://sites.google.com/site/riskofbiastool/home. Accessed December 1, 2014.
   Google Scholar
• Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990; 6: 5–30.
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
   PubMedGoogle Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65–94.
   PubMed Web of Science ®Google Scholar
• Shen ZX, Huang X, Baccarani M, et al. Higher rate of major molecular response (MMR) with nilotinib vs imatinib in Chinese patients (PTS) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP): Enestchina 24-mo update. Haematologica 2014; 99: 332–333: Abstract.
   Web of Science ®Google Scholar
• Schwarz M, Kim TD, Mirault T, et al. Elevated risk of peripheral artery occlusive disease (PAOD) in nilotinib treated chronic phase chronic myeloid leukemia (CML) patients assessed by ankle-brachial-index (ABI) and duplex ultrasonography. Blood 2012; 22(21): Abstract.
   Google Scholar
• Saglio G, Le Coutre P, Cortes J, et al. Safety and tolerability of dasatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): Pooled analysis of over 2400 patients. Haematologica 2014; 99: 329: Abstract.
   PubMed Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood 2013; 122(21): Abstract.
   PubMed Web of Science ®Google Scholar
• Rosti G, Gugliotta G, Castagnetti F, et al. . Five-year results of nilotinib 400 mg bid in early chronic phase chronic myeloid leukemia (CML): high rate of deep molecular response – update of the gimema CML WP trial cml0307. Blood 2012; 120(21): Abstract.
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12: 337–340.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Gagnieu MC, Heiblig M, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort. Blood 2013; 122(21): Abstract #4020.
   Google Scholar
• Mauro M, Radich J, Cortes JE, et al. Single-arm, open-label, multicenter study of deep molecular response (MR4.5) with nilotinib in adult patients (PTS) with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP): Enestnext study update. Blood 2013; 122(21): Abstract #4015.
   Google Scholar
• Levato L, Cantaffa R, Kropp MG, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia. Blood 2012; 120(21): Abstract #1679.
   Web of Science ®Google Scholar
• Labussiere-Wallet H, Guillermin Y, Etienne M, et al. Analysis of clinical arterial and metabolic parameters in chronic phase cml patients on nilotinib in a single center cohort. Blood 2012; 120(21): Abstract #3756.
   Web of Science ®Google Scholar
• Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316–1321.
   PubMed Web of Science ®Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Efficacy and safety of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV. Haematologica 2014; 99: 236. Abstract #S676.
   Web of Science ®Google Scholar
• Jeon YW, Lee SE, Choi SY, et al. Peripheral arterial occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib. Blood 2013; 122(21): Abstract #4018.
   Google Scholar
• Jain P, Kantarjian HM, Romo CG, et al. Patterns of non-hematological adverse effects in patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with ponatinib-experience at a single institution. Blood 2013; 122(21): Abstract #4019.
   Google Scholar
• Hadzijusufovic E, Herndlhofer S, Aichberger KJ, et al. Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph + CML. Blood 2011; 118(21): Abstract #2753.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Baccarani M, Brummendorf TH, et al. Deep molecular responses in patients with newly diagnosed chronic myeloid leukemia receiving nilotinib as assessed within the EUTOS laboratory network in the ENEST1st study. Blood 2013; 122(21): Abstract #4030.
   Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553–561.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783–1796.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014; 89: 947–953.
   PubMed Web of Science ®Google Scholar
• Branford S, Kamel-Reid S, Bendit I, et al. Early molecular response predicts achievement of undetectable BCR-ABL in patients (PTS) with chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib: 3-year follow-up of ENESTCMR. Haematologica 2014; 99: 532: Abstract #S1361.
   Web of Science ®Google Scholar
• Bocchia M, Galimberti S, Aprile L, et al. Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? Haematologica 2014; 99: 533–534. Abstract #S1363.
   Web of Science ®Google Scholar
• Aprile L, Puccetti L, Galimberti S, et al. Atherothrombotic risk and TKI treatment in chronic myeloid leukemia patients: a role for genetic predisposition and pro-inflammatory/pro-oxidative status? Blood 2013; 122(21): Abstract #1482.
   Web of Science ®Google Scholar
• Hiwase DK, Yeung DT, Carne L, et al. Hypercholesterolemia in imatinib intolerant/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood 2013; 122: Abstract #1503.
   Web of Science ®Google Scholar
• Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347–1348.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075–2088.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841–851.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Hehlmann R, Gambacorti-Passerini C, et al. Baseline characteristics of patients with chronic myeloid leukemia in a prospective observational study (simplicity). Blood 2013; 122(21): Abstract #4026.
   Google Scholar
• Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007; 31: 1770–1772.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Yeung DT, Carne L, et al. Hypercholesterolemia in imatinib intolerant/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood 2013; 122(21): Abstract #1503.
   Web of Science ®Google Scholar
• Breccia M, Colafigli G, Molica M, et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol 2015; 90: E100–E101.
   PubMed Web of Science ®Google Scholar